Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

The trial, a 20-week study assessing lamotrigine in DLB, will use change in Clinical Dementia Rating-Sum of Boxes as the primary efficacy end point, with several other notable secondary outcomes.

Phase 2a Trial to Test Effects of Antiseizure Medication Lamotrigine in Dementia With Lewy Bodies

Videos

The epilepsy specialist and Cleveland Clinic’s Chief Research and Information Officer discussed the wide-spread applicability of scalp EEG and the potential for machine learning models to help predict epilepsy surgery outcomes. [WATCH TIME: 4 minutes]

Scalability of Scalp EEG as a Tool for Epilepsy Surgery Outcomes: Lara Jehi, MD, MHCDS

For more than a 2-year treatment period, 95% of patients reported taking at least 95% of their daily medications with zilucoplan.

Medication Compliance High With Self-Administered Ziluocoplan in Myasthenia Gravis

Over a 12-month treatment period, patients on deferiprone demonstrated decreased blood ferritin and hippocampal QSM but caused accelerated cognitive decline and increased regional brain atrophy.

Negative Effect of Deferiprone Points to Impact of Iron Lowering in Alzheimer Disease

The neurologist in the Headache Center at Cleveland Clinic shared her post perspective on the 2024 AHS Scottsdale meeting which highlighted advancements in headache medicine and the growing impact of the field on patient care. [WATCH TIME: 5 minutes]

Highlights on Exploring Advances in Headache Medicine from AHS Scottsdale 2024: MaryAnn Mays, MD

Dean and chief academic officer at the University of Miami Miller School of Medicine.

The dean and chief academic officer at the University of Miami Miller School of Medicine discussed the university’s investment in computational biology to advance aging and neuroscience research. [WATCH TIME: 5 minutes]

Driving Innovation in Aging and Neurodegenerative Research: Henri Ford, MD, MHA 

Here's the latest multidisciplinary multiple sclerosis (MS) research from the International Journal of MS Care.

Research from IJMSC September 2024

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AANEM 2024

CTAD 2024

MDS 2024

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Management of Insomnia in Female Patients  

An expert discusses the frontline management of insomnia in female patients.

Charlene Gamadelo, MD, provides an overview of insomnia and discusses the prevalence by race and gender, the variations in presentation of symptoms in patients, and the pathways involved in sleep wakefulness cycles.

Overview of Insomnia

A neurology expert describes why women experience insomnia at higher rates than men and how co-occurrence of insomnia with other medical conditions, including psychiatric disorders, can affect occurrence. 

Insomnia in Female Patients

An overview of the impact insomnia can have on female patient’s quality of life and how they communicate sleep disturbance concerns with health care professionals.

Quality of Life and Patient Communication Regarding Insomnia

An overview of the different roles of health care professionals in the management of female patients suffering from insomnia.

Managing Female Patients With Insomnia

Charlene Gamadelo, MD, provides an overview of commonly utilized insomnia treatment modalities in the treatment of female patients with insomnia.

Approach to Treating Female Patients With Insomnia

Charlene Gamadelo, MD, describes the different categories of FDA approved treatments for insomnia along with challenges associated with these treatments.

Challenges Associated With Insomnia Treatments

An overview of dual orexin receptor agonists (DORAs) therapy for the treatment of insomnia in female patients.

Insomnia Treatment: DORAs

Charlene Gamaldo, MD, discusses patient criteria for selecting a dual orexin receptor agonist (DORA) for insomnia treatment.

Insomnia Treatment Selection: DORA

Lasso - DMD Peers and Perspectives NSP-21-NRD0157

Clinical

 video series brings together pairs of expert clinicians and physicians to independently provide their insights on the latest and most up-to-date clinical care for specific neurologic diseases and disorders.

Approach to Treating Female Patients With Insomnia

EP: 1.Overview of Insomnia

EP: 2.Insomnia in Female Patients

EP: 3.Quality of Life and Patient Communication Regarding Insomnia

EP: 4.Managing Female Patients With Insomnia

EP: 5.Approach to Treating Female Patients With Insomnia

EP: 6.Challenges Associated With Insomnia Treatments

EP: 7.Insomnia Treatment: DORAs

EP: 8.Insomnia Treatment Selection: DORA